Cannabis Clinical Trials

Cannabis is one of the newest industries in Canada, and it’s becoming one of the most tech-savvy thanks to data-crunching gurus like the developers at Knalysis Technologies. The company based in Fredericton, New Brunswick has developed an app that could revolutionize the cannabis experience for both medical patients and recreational connoisseurs. The Knalysis Wellness Tracker helps […]

by

Cannabis is one of the newest industries in Canada, and it’s becoming one of the most tech-savvy thanks to data-crunching gurus like the developers at Knalysis Technologies. The company based in Fredericton, New Brunswick has developed an app that could revolutionize the cannabis experience for both medical patients and recreational connoisseurs. The Knalysis Wellness Tracker helps […]

by

SAN DIEGO, Aug. 3, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM) has entered into a Clinical Study Agreement (CSA) with the University of British Columbia in Canada to begin a […]

by

Zynerba Pharmaceuticals, Inc (NASDAQ: ZYNE) gave investors an update on its clinical program this week. Like weeds, specialty pharmaceutical companies have sprung up and engaged in developing commercially viable therapies based on cannabinoids, a primary compound found in cannabis. In light of the impending results from Zynerba, below is a list of prominent cannabinoid product […]

by

JERUSALEM, August 3, 2017 /PRNewswire/ — Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pillâ„¢ platform technology, announces the results from a Phase I clinical trial of AP-CBD/THC, its Accordion Pill platform with cannabidiol (CBD) and tetrahydrocannabinol (THC), the two primary cannabinoids […]

by

NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a Clinical Study Agreement (CSA) with the University of British Columbia in Canada to begin a clinical trial with its CanChew Plus® cannabidiol (CBD) chewing gum […]

by

“We’re excited about these encouraging results from our Phase 1 study of AP-CBD/THC as it shows the Accordion Pill platform is well suited to safely deliver CBD and THC with significant improvements in exposure compared with Sativex®,” said Nadav Navon, Ph.D., Chief Operating Officer of Intec Pharma. “We are particularly pleased to see the reduction […]

by

“We’re excited about these encouraging results from our Phase 1 study of AP-CBD/THC as it shows the Accordion Pill platform is well suited to safely deliver CBD and THC with significant improvements in exposure compared with Sativex®,” said Nadav Navon, Ph.D., Chief Operating Officer of Intec Pharma. “We are particularly pleased to see the reduction […]

by

VANCOUVER, BC–(Marketwired – August 01, 2017) – Aequus Pharmaceuticals Inc., (“Aequus”) (TSX VENTURE: AQS)(OTCQB: AQSZF), a specialty life sciences company focused on providing patients with differentiated and enhanced delivery systems for existing and approved drugs, and Scientus Pharma Inc., (“Scientus”), a biopharmaceutical company focused on RD and product commercialization for extracts and formulations related to […]

by